Furthermore, blocking PI3K signaling by alpelisib or inavolisib reduced SREBP1 and SCD-1 expression, suggesting that HER2/PI3K/AKT/mTOR signaling regulated the de novo lipogenesis machinery in HER2-positive breast cancer cells. This evidence concerns the gene ERBB2 and breast carcinoma.